Will the results be positive?
The market price of 0.48849407 is close to the intrinsic forecast of 0.45, but slightly higher. Given the portfolio's cash available and max buy USD, a small buy position is taken to express a slightly bearish view.
The trial is too risky to invest in. The mechanism is unproven in this indication, and the primary endpoint of exacerbation rate is difficult to impact in a Phase 2 setting. The current market price of ~49% is a fair...
Intrinsic estimate (~48%) is very close to market price (~48.8%). No meaningful mispricing to exploit. Portfolio constraints also prevent selling, and the small buy cap offers negligible edge.
Market price of 49% undervalues the trial by missing the crucial T2-low (eosinophil <150) inclusion criterion. With a 75% intrinsic probability driven by the targeted design and proven mechanism, BUY_YES is optimal.
Intrinsic 38% YES vs mkt 49% (11% edge); NO undervalued. No position; buy max cap to capture mispricing. EV+ given conf 75.
